Loading provider…
Loading provider…
Neurology Physician in Kansas City, MO
NPI: 1225221922Primary Practice Location
SAINT LUKE'S SOUTH HOSPITAL
12300 Metcalf Ave, Overland Park, KS
Primary Employer
Saint Lukes Primary Care at Home
saintlukeskc.org
HQ Phone
Get MD Samuel's Phone Numberphone_androidMobile
Get MD Samuel's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardKS State Medical License
MO State Medical License
MO State Medical License
2023 - 2026
KS State Medical License
2023 - 2025
NJ State Medical License
2011 - 2023
NY State Medical License
2008 - 2011

American Board of Psychiatry and Neurology
Neurology
Ohio State College of Medicine
medicine.osu.edu
Medical School
Until 2005
Memorial Sloan Kettering Cancer Center
Fellowship • Neuro-Oncology
2009 - 2011
NYU Grossman School of Medicine
med.nyu.edu
Residency • Neurology
2006 - 2009
Zucker School of Medicine at Hofstra/Northwell
Internship • Internal Medicine
2005 - 2006
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 57 | 120 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 35 | 51 |
| 3 | G2212Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 23 | 33 |
| 4 | 99205New patient office or other outpatient visit, typically 60 minutes | 15 | 15 |
Authors: Laszlo Mechtler, David Tran, David Baskin, John Sampson, Michael Yellin, Lynn Ashby, Jan Drappatz, Donald Orourke, Fabio Iwamoto
Journal: Lancet Oncol
Publication Date: 2017-08-23
Headache in patients with cancer.
Authors: Edward Avila, Jerome Graber
Publication Date: 2010-10-08
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Temozolomide, OTHER: Laboratory Biomarker Analysis, OTHER: Quality-of-Life Assessment, DRUG: Veliparib, OTHER: Placebo Administration
Lead Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI), Daiichi Sankyo
Intervention / Treatment: DRUG: efatutazone
Lead Sponsor: Hackensack Meridian Health
Collaborators: NovoCure Ltd.
Intervention / Treatment: DRUG: Temozolomide, DEVICE: NovoTTF-200A, RADIATION: 3D conformal or intensity modulated radiation therapy (IMRT)
Journal: JAMA Oncol